Heterozygosity and/or homozygosity for mutations at the genes of the enzyme
s involved in homocysteine metabolism may confer an increased risk for thro
mbosis by causing hyperhomocysteinemia. Although the mutations related to h
omocysteine metabolism possibly increase the risk of stroke, the data are c
onflicting and there are very few reports linking these defects to acute st
roke in children. We aimed to study the role of these mutations in Turkish
children with ischemic stroke. Forty-six patients having cerebral infarct w
ere clinically diagnosed, and the infarction verified with magnetic resonan
ce imaging of the brain was included in the study. All patients were below
the age of 18 (10 months to 18 years). Sixty-eight controls, consecutively
selected among healthy unrelated subjects from the same geographic area of
Turkey without personal and family history of thrombosis, stroke or Behest'
s disease, were included. Genotyping for the common mutations was carried o
ut by the methods described previously. There was no difference between the
pediatric stroke patients and controls for the distribution of methylene t
etrahydrofolate reductase (MTHFR) 677 C-T, MTHFR 1298 A-C, methylene tetrah
ydrofolate dehydrogenase (MTHFD) 1958 G-A and methionine synthase reductase
(MTRR) 66 A-G alleles. There was no risk for double alterations (MTHFR 677
C-T vs. 1298 A-C) after individuals with FV 1691 A mutation is excluded. T
welve of the 46 patients were found to carry FV 1691 A mutation (26.0%), on
e being homozygote. The cerebral infarct risk for FV 1691 A was found to be
6.4 (CI 95% 1.7-23.0). Eight of the 46 patients were found to carry PT 202
10 A mutation (16.6%). Two of the FV 1691 A heterozygous patients carried P
T 20210 A mutation at the same time (4.2%). As a conclusion, we can say tha
t FV 1691 A and PT 20210 A mutations are important and must be included to
the routine analysis of pediatric stroke patients. (C) 2001 Elsevier Scienc
e Ltd. All rights reserved.